Genvion has added to its contract development and manufacturing expertise with the addition of new spray drying and Wurster coating technology.
The Canadian contract development and manufacturing organization (CDMO), which specializes in cytotoxic and potent solid dosage forms, has added new capabilities bringing on-line spray dryers and Wurster coaters following the successful installation and validation of the advanced manufacturing equipment at its new, state-of-the-art 80,000 sq. ft facility.
The new equipment gives the CDMO spray drying capabilities in both R&D and commercial manufacturing.
“Customer demand for GMP spray drying is increasing because of the need to support poorly soluble drugs. This latest investment diversifies Genvion’s capability to address these demands and broadens our manufacturing services, whilst also boosting our existing high containment and cytotoxic niche expertise,” Genvion vice president, Tony Cocci said. “Market response to the investment in our capabilities has been very encouraging with both existing and new customers taking advantage of our wider portfolio of services, particularly our ability to take customers from development through to commercial manufacture.”
The investment, expected to be close to $1.5m when taking into account both the spray drying and Wurster equipment, is part of Genvion’s ongoing plans to expand its GMP manufacturing capabilities at its facility in Winnipeg, Canada and comes in direct response to customer demand for spray drying and drug layering from big pharma companies through to small specialty firms.
From its GMP, Health Canada and FDA approved facility in Winnipeg, Canada, Genvion’s expert team supports customers in North America, Europe, the Middle East and North Africa with processing options for solid dosage forms. Its technologies include containment dispensing booths, high-shear granulators, fluid-bed granulators/dryers, roller compactors, IBC blenders, tablet presses, capsule fillers and aqueous/solvent-based film coaters.